Apigenin Prevents Acetaminophen-Induced Liver Injury by Activating the SIRT1 Pathway

Licong Zhao1,2†, Jiaqi Zhang3†, Cheng Hu3†, Tao Wang1, Juan Lu1, Chenqu Wu1, Long Chen3, Mingming Jin3, Guang Ji5†, Qin Cao1* and Yuanye Jiang1*

1 Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 2 Department of Second Clinical College, China Medical University, Shenyang, China, 3 Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 4 Shanghai University of Medicine & Health Sciences of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China, 5 Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Acetaminophen (APAP) overdose is the main cause of acute liver failure. Apigenin (API) is a natural dietary flavonol with high antioxidant capacity. Herein, we investigated protection by API against APAP-induced liver injury in mice, and explored the potential mechanism. Cell viability assays and mice were used to evaluate the effects of API against APAP-induced liver injury. Western blotting, immunofluorescence staining, RT-PCR, and Transmission Electron Microscope were carried out to determine the signalling pathways affected by API. Analysis of mouse serum levels of alanine/aspartate aminotransferase (ALT/AST), malondialdehyde (MDA), liver myeloperoxidase (MPO) activity, glutathione (GSH), and reactive oxygen species (ROS) revealed that API (80 mg/kg) owned protective effect on APAP-induced liver injury. Meanwhile, API ameliorated the decreased cell viability in L-02 cells incubated by APAP with a dose dependent. Furthermore, API promoted SIRT1 expression and deacetylated p53. Western blotting showed that API promoted APAP-induced autophagy, activated the NRF2 pathway, and inhibited the transcriptional activation of nuclear p65 in the presence of APAP. Furthermore, SIRT1 inhibitor EX-527 reduced protection by API against APAP-induced hepatotoxicity. Molecular docking results indicate potential interaction between API and SIRT1. API prevents APAP-induced liver injury by regulating the SIRT1-p53 axis, thereby promoting APAP-induced autophagy and ameliorating APAP-induced inflammatory responses and oxidative stress injury.

Keywords: apigenin, acetaminophen-induced liver injury, SIRT1 pathway, flavonol, antioxidant, SIRT1-p53 axis, inflammatory response, oxidative stress

INTRODUCTION

Acetaminophen (APAP, paracetamol) is a widely used antipyretic and analgesic non-prescription drug. It is generally safe and effective, but long-term and/or large doses will lead to severe acute liver injury that can eventually develop into liver failure and even death (Nourjah et al., 2006; Fontana, 2008). Approximately 2,600 people are reportedly hospitalized each year due to overdose of APAP,
56,000 people are seen in the emergency room, and ~500 people die (Lee, 2008). In China, due to the population, medical conditions, and medical knowledge, a large number of high-dose APAP cases occur annually, and liver damage has become a serious health problem (Shen et al., 2019). In the human body, the main cause of liver damage is due to APAP consuming glutathione (GSH) in the liver, causing cellular oxidative stress and liver damage (Kanno et al., 2017). A high dose of APAP produces N-acetyl-P-phenylpropanimide (NAPQI) under oxidation of the cytochrome P450 enzyme system. NAPQI is a highly toxic X-ray product that can be used in combination with glutathione to deplete APAP. Binding to proteins in hepatocytes forms protein conjugates, causing intracellular oxidative stress, mitochondrial and DNA damage, eventually leading to liver necrosis (Walker et al., 2017).

4',5,7-trihydroxyflavone (Apigenin, API, Versulin) is a well-known flavonoid isolated from Matricaria chamomilla. In our previous research, we found that flavonoids can protect against various liver diseases, especially acetaminophen-induced liver damage, via anti-oxidation and anti-inflammatory mechanisms (Jing et al., 2018; Shi et al., 2018; Zhao et al., 2019). API can protect against various liver injuries caused by alcohol (Wang et al., 2017), lipopolysaccharide (Zhou et al., 2017), ischemia/reperfusion (Tsaroucha et al., 2016), and CCl4 (Simeonova et al., 2014). Furthermore, API can protect against liver injury in an APAP mouse model, but its specific mechanism of action remains unknown (Yang et al., 2013).

Sirtuin 1 (SIRT1) regulates protein deacetylation, participates in protein transcription and translation, regulates cell proliferation, oxidative stress, and metabolism, and plays an important role in metabolic diseases, tumors, and cardiac function (Consiglio et al., 2014; Cui et al., 2016; Qin et al., 2016). Rada et al. found that overexpression of SIRT1 ameliorated hepatic toxicity induced by APAP, and inhibits inflammation responses and oxidative stress (Rada et al., 2018). A previous study also reported that SIRT1 suppresses p53 acetylation in ischemia/reperfusion liver injury (Nakamura et al., 2017). However, the mechanism in APAP liver injury is still unknown. Furthermore, the structure of resveratrol (RSV) indicates that RSV molecules may modulate the interaction between the 7-amino-4-methylcoumarin peptide and the extended N-terminal domain of SIRT1, and promote SIRT1 activity (Cao et al., 2015; Naini et al., 2019). However, the correlation between apigenin and SIRT1 is still not clear.

Herein, we investigated apigenin protection mechanisms against APAP-induced liver injury. We also investigated the participation of SIRT1 in this process.

**Materials and Methods**

**Drugs and Reagents**

Apigenin (purity >99.5%) was purchased from Shanghai Hitsanns Co., Ltd (Shanghai, China). Kits for alanine aminotransferase (ALT), aspartate aminotransferase (AST), malondialdehyde (MDA), myeloperoxidase (MPO), and glutathione (GSH) were purchased from Nanjing Jiancheng Bioengineering Institute (Nanjing, China). H2DCFDA, RPMI1640, and fetal bovine serum (FBS) were purchased from Life Technology (Carlsbad, CA, USA). A Pierce BCA Protein Assay Kit was purchased from Thermo Fisher Scientific (Waltham, MA, USA). EX-527 was purchased from Sigma-Aldrich (St. Louis, MO, USA). Whole-cell protein extraction kits and enhanced chemiluminescence kits were obtained from Millipore (Darmstadt, Germany). Antibodies for immunoblotting, including β-actin (#4970), Lamin B (#13435), SIRT1 (#8469), p53 (#2524), ac382-p53 (#2525), NRF2 (#12721), and p65 (#8242) were purchased from Cell Signaling Technology (Danvers, MA, USA; all 1: 1,000 dilutions). Enzyme-linked immunosorbent assay (ELISA) kits were purchased from RapidBio (West Hills, CA, USA). TRizol reagent was purchased from Life Technology (Carlsbad, CA, USA). PrimeScript RT Master Mix and SYBR Premix Ex Taq were purchased from TaKaRa (Shiga, Japan). APAP, NAPQI, 3-(4,5-dimethyl-thiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT), and other reagents were purchased from Sigma-Aldrich unless otherwise indicated.

**Experimental Animals**

C57BL/6 mice (20 ± 2 g) were purchased from Shanghai Laboratory Animal Center (Shanghai, China) and fed according to guidelines approved by the Experimental Animal Ethical Committee of Shanghai University of Traditional Chinese Medicine. They were raised in a constant temperature and humidity room (22 ± 1°C, 65 ± 5% humidity) with standard diet and water. The protocol was reviewed and approved by the Experimental Animal Ethical Committee of Shanghai University of Traditional Chinese Medicine (Permit Number: PZSHUTCM190315014).

**Animal Treatment**

Forty mice were randomly divided into five groups; (1) vehicle control, (2) APAP (400 mg/kg), (3) APAP (400 mg/kg) + API (20 mg/kg), (4) APAP (400 mg/kg) + API (80 mg/kg), and (5) API (80 mg/kg). Mice were pre-administered orally with API (20 or 80 mg/kg per day) for 7 consecutive days. On the last day, mice were orally administered a single dose of APAP (400 mg/kg) after administration of API for 1 h. Animals were sacrificed 6 h after APAP intoxication and plasma and liver tissues were collected.

To assess the role of SIRT1 in regulating APAP-induced liver injury, 48 mice were randomly divided into six groups; (1) Dimethyl sulfoxide (DMSO) (2) DMSO + APAP (400 mg/kg), (3) DMSO + APAP (400 mg/kg) + API (20 mg/kg), (4) DMSO + APAP (400 mg/kg) + API (80 mg/kg), (5) EX-527 (10 mg/kg), (3) EX-527 (10 mg/kg) + APAP (400 mg/kg), and (5) EX-527 (10 mg/kg) + APAP (400 mg/kg) + API (80 mg/kg). Mice were pre-administered orally with API (80 mg/kg per day) or injected intraperitoneally with DMSO or EX-527 (10 mg/kg) for 7 consecutive days. On the last day, mice were orally given a single dose of APAP (400 mg/kg) after administration of API for 1 h. Animals were sacrificed 6 h after APAP intoxication and plasma and liver tissues were collected.
Biochemical Analysis for Blood and Liver

Blood and livers were withdrawn after cardiac puncture. Blood samples were kept at room temperature for 2 h and then centrifuged at 840 g for 10 min to collect serum. Part of liver tissue was fixed in formalin and the rest was snap-frozen in liquid nitrogen and stored at -80°C. ALT, AST in serum and MDA, MPO, ROS, GSH in liver were measured by kits, according to manufacturer’s protocols (Nanjing Jiancheng Bioengineering Institute, Nanjing, China).

Liver Histological Observation

Liver histological was observed to evaluate liver damage degree and structural changes under a light microscope (Olympus, Tokyo, Japan) after fix, dehydration, paraffin embedded, section, and H&E staining.

Cell Culture

The L-02 cell line was derived from an adult human normal liver (Cohen et al., 1997) (Cell Bank, Type Culture Collection of Chinese Academy of Sciences, Shanghai). L-02 cells were cultured in RPMI1640 supplemented with 10% [v/v] fetal bovine serum, 2 mM glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin, and incubated at 37°C in a humidified atmosphere containing 5% CO2.

Cell Viability Assay

L-02 cells were plated into 96-well plates at an initial density of 5,000 cells per well. Cells were pre-incubated with EX-527 or DMSO for 15 min, then incubated with or without API for another 15 min after attachment, and finally incubated with APAP or NAPQI for different time periods. After treatment, cells were incubated with 500 μg/ml MTT for 4 h. Blue formazan was dissolved in 10% SDS-5% isobutanol-0.01M HCl, and plates were scanned on a microplate reader (Thermo Scientific) with 630 nm as a reference. Cell viability was normalised as a percentage of control wells.

RNA Isolation and Quantitative Real-Time PCR (qRT-PCR)

RNA was isolated using TRIzol reagent (Invitrogen) according to manufacturer’s instructions and reverse-transcribed using a miScript Reverse Transcription Kit. qRT-PCR was performed using a SYBR Premium Ex Taq II kit (TaKaRa) on an ABI PRISM 7500 Sequence Detection System (Applied Biosystems). All reactions were performed in triplicate and the mean value was used to calculate expression levels after normalisation against β-actin.

Protein Extraction and Western Blot Analysis

L-02 cells were lysed using RIPA buffer and protein concentration was determined using a BCA protein assay kit. Approximately 30 μg of protein from each sample was separated by 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene fluoride (PVDF) membrane. Membranes were blocked with 5% skimmed milk in TBST and incubated with primary antibodies overnight at 4°C. Membranes were incubated with the corresponding secondary antibody for 1 h at room temperature and washed in TBST. Protein signals were detected using Super ECL Plus Detection Reagent.

Enzyme-Linked Immunosorbent Assay (ELISA)

The levels of inflammatory cytokines IL-6, TNF-α, and MCP-1 in blood were determined with an ELISA kit (Nanjing Jiancheng Bioengineering Institute), according to standard protocols.

Immunofluorescence Analysis

Immunofluorescence staining was performed as previously reported (Shah et al., 2015). Briefly, cells were washed twice with 0.01 M PBS for 15 min followed by addition of proteinase K and blocking solution. Primary antibodies, as described in the above paragraph (1:100 in PBS), were added and incubated at 4°C overnight. After washing with PBS, secondary antibodies (FITC- and TRITC-conjugated, Santa Cruz Biotechnology, 1:50 in PBS) were then applied at room temperature for an additional 90 min. Slides were washed twice with PBS for 5 min, 4’,6-diamidino-2-phenylindole (DAPI) was applied to stain nuclei, and glass cover slips were mounted on slides with mounting medium. Images were captured using a Fluoview FV 1000 confocal microscope (Olympus, Japan).

Molecular Docking

A molecular docking study was performed to investigate interactions between API and SIRT1 using Autodock vina 1.1.2 (Trott and Olson, 2010). The three-dimensional (3D) coordinates of SIRT1 (PDB ID: 5BTR) were retrieved from the RCSB Protein Data Bank. The 3D structure of API was drawn using ChemBio 3D Ultra 14.0 and converted to a 3D structure by ChemBio 3D Ultra 14.0. The AutoDockTools 1.5.6 package (Sanner, 1999; Morris et al., 2009) was employed to generate docking input files. The binding site of SIRT1 was identified as centre_x: -20.454, centre_y: 58.86, and centre_z: 9.056 with dimensions size_x: 15, size_y: 15, and size_z: 15. To increase the accuracy of the calculation, the value of exhaustiveness was set to 20, and default parameters were used unless otherwise mentioned. The best-scoring pose as judged by Vina docking score was chosen and further analyzed using PyMoL 1.7.6 software.

Statistical Analysis

Data were expressed as the mean ± standard error of the mean (SEM). Significant differences were determined by One-Way ANOVAs with LSD post hoc tests; and P < 0.05 is considered to be statistically significant.

RESULTS

Protective Effect of API In Vivo

APAP significantly increased the levels of ALT/AST in mouse serum, whereas they were decreased significantly in the presence of API (Figure 1B) at 6 h and mice treated with API alone did
FIGURE 1 | Protective effect of apigenin (API) in vivo. (A) Structural formula of API. The molecular formula and weight of API is C_{15}H_{10}O_{5} and 270.24 g/mol. (B) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities at 6 h after administration with acetaminophen (APAP). (C) Typical images of H&E staining of liver segments (×200 and ×400 magnification). (D) Myeloperoxidase (MPO) activity in mice liver tissue was detected. (E) Reactive oxygen species (ROS) levels in mice liver tissue was detected. (F) Malondialdehyde (MDA) activity in mice liver tissue was detected. (G) Glutathione (GSH) levels in mice liver tissue was detected. (H) Liver protein levels of SIRT1 and Acetyl-p53 determined by western blot. (I) Liver protein levels of LC3-II/I assessed by western blot. (J) Protein expression of p65 and nuclear localisation of NRF2 determined by western blot and quantified. (K) Phosphorylation of NRF2 and p65 determined by western blot and quantified. (L) Serum protein concentrations of IL-6, TNF-α, and MCP-1 determined by enzyme-linked immunosorbent assay (ELISA) in mice. (M) Liver mRNA levels of IL-6, TNF-α, and MCP-1 determined by real-time PCR (RT-PCR) in mice. (N) Liver mRNA levels of GCLC, GCLM, and HO-1 determined by RT-PCR. Data are expressed as mean ± SEM (n = 8; *p < 0.05, **p < 0.01, ***p < 0.001 compared to vehicle; #p < 0.05, ##p < 0.01, ###p < 0.001 compared to APAP).
not display any obvious differences compared to the vehicle group. It was found in H&E staining results that intrahepatic haemorrhage and destruction of liver structures occurred in APAP group, whereas these symptoms were ameliorated by API. This observation further confirmed the protective effects of API against APAP-induced liver injury in mice (Figure 1C).

Next, we found APAP lead the increasement of MPO, MDA, and ROS, while administration of API suppressed the level of MPO, MDA, and ROS (Figures 1D–F). In addition, API improved GSH levels in mouse liver compared with APAP (Figure 1G).

These results indicated that API alleviated APAP-induced liver injury in mice (Figure 1C). Next, APAP decreased protein expression levels of SIRT1 and p53 acetylation, while administration of API promoted protein expression of SIRT1 and inhibited p53 acetylation (Figure 1H). Figure 1I showed that APAP upregulated the expression of LC3-II/I (autophagy-related proteins) in liver tissues, whereas treatment with API appeared to promote expression of these proteins in liver tissues. Furthermore, inflammatory response and oxidative stress-related proteins were detected by western blot. Figures 1J, K showed that API promoted the phosphorylation of p65 and increased the level of nuclear NRF2 and HO-1, which indicated that API induced the transcriptional activation of NRF2. Heme oxygenase 1 (HO-1) and catalytic or modified subunits of GCL are downstream genes regulated by NRF2 (Kaspar et al., 2009). As shown in Figure 1N, APAP suppressed mRNA levels of GCLM, and APAP showed no significant effect on mRNA levels of GCLC or HO-1. Moreover, API increased the mRNA levels of GCLM and HO-1 significantly. Furthermore, API inhibited phosphorylation of p65 and decreased the level of nuclear p65 increased by APAP (Figures 1J, K). ELISA results showed that concentrations of IL-6, TNF-α, and MCP-1 in serum increased significantly in the presence of APAP (Figure 1L). Additionally, Figure 1M showed that API reversed the increased mRNA levels induced by APAP.

API Prevents APAP-Induced Cytotoxicity

As shown in Figures 2A, B, APAP (10 mM) and NAPQI (200 µM; a metabolite product of APAP) both decreased cell viability in L-02 cells. API reversed the suppression of cell viability caused by APAP and NAPQI in L-02 cells in a concentration-dependent manner.
manner. Next, western blot results indicated no obvious change in SIRT1 protein levels compared with control and APAP groups in L-02 cells. After treatment with API, protein levels of SIRT1 were significantly increased. API also reversed APAP-induced p53 acetylation in L-02 cells (Figure 2C). Immunofluorescence analysis of SIRT1 and acetyl-p53 in L-02 cells confirmed these results (Figures 2D, E).

Furthermore, western blotting showed that API enhanced the APAP-induced increases in LC3-II/I, suggesting that API promoted APAP-induced autophagy in L-02 cells (Figure 2F). Immunofluorescence analysis revealed increased levels of autolysosomes (red) and autophagosomes (green) in L-02 cells incubated with APAP for 48 h, and more significantly with API (Figures 2G, H). Transmission electron microscopy (TEM) of autophagic vacuoles in L-02 cells confirmed these results (Figures 2I, J). Furthermore, inflammatory response and oxidative stress-related proteins were detected by western blotting in L-02 cells. Figures 3A, B indicated that API promoted the phosphorylation of NRF2 and increased the levels of nuclear NRF2 protein, suggesting that API induced the transcriptional activation of NRF2.

Figure 3D showed that APAP increased cellular ROS levels in L-02. Meanwhile, API (50 μM) inhibited enhanced ROS levels induced by APAP in L-02 cells. Furthermore, API suppressed mRNA levels of GCLM and HO-1. APAP had no significant effect on mRNA levels of GCLC. Moreover, API increased the mRNA levels of GCLC, GCLM, and HO-1 significantly, compared with the APAP group (Figure 3E). Figures 3A, B showed that API inhibited the phosphorylation of p65 and decreased the level of nuclear p65 increased by APAP. Meanwhile, APAP increased mRNA levels of IL-6, TNF-α, and MCP-1 in L-02 cells, while API reversed these APAP-induced increases (Figure 3C). Accordingly, these results suggested that API up-regulated SIRT1, promoted autophagy, and ameliorated inflammatory responses and oxidative stress in vitro.

**API Prevents Hepatotoxicity Via SIRT1 In Vitro**

To explore whether API plays a role via the SIRT1 pathway, we used SIRT1 inhibitor EX-527 to inhibit SIRT1 expression. As expected, western blot data showed that EX-527 (10 μM) significantly down-regulated SIRT1 expression in L-02 cells (Figure 4A). MTT assessment showed that the hepatocyte-protective effect of API was inhibited by treatment with EX-527, and a single treatment with EX-527 aggravated cell injuries induced by APAP (Figure 4B). Western blot results also indicated that EX-527 reversed inhibition of p53 acetylation caused by API in L-02 cells (Figure 4C). Immunofluorescence analysis of SIRT1 and acetyl-p53 in L-02 cells confirmed these results (Figures 4D, E).

To clarify the relationship between SIRT1 and autophagy, we analyzed protein levels of LC3-II/I by western blot. The results suggested that EX-527 inhibited autophagy induced by API and APAP in L-02 cells (Figure 4F). Immunofluorescence staining and TEM also showed that EX-527 reversed the autophagy effects induced by API and APAP (Figures 4G–J). Analysis of phosphorylation and nuclear localisation of NRF2 showed that EX-527 repressed transcriptional activation of NRF2 induced by API (Figures 5A, B). Furthermore, Figure 5D showed that EX-527 up-regulated ROS levels in L-02 cells, which were decreased by API. In addition, qRT-PCR indicated that EX-527 suppressed
mRNA levels of GCLM, GCLC, and HO-1 significantly (Figure 5E).

We then measured the levels of p65 in L-02 cells. Western blots revealed that EX-527 promoted the phosphorylation of p65 and nuclear translocation of p65 in L-02 cells (Figures 5A, B). Meanwhile, EX-527 significantly increased mRNA levels of IL-6, TNF-α, and MCP-1 in L-02 cells (Figure 5C). From these observations, it would appear that the SIRT1 inhibitor EX-527 reversed the protective effects of API by promoting p53 acetylation, inhibiting autophagy, and aggravating inflammatory responses and oxidative stress in L-02 cells.

**Theoretical Binding Mode of API and SIRT1**

**Figures 6A, B** represented the theoretical binding mode of apigenin in the binding site of SIRT1. API is positioned in the hydrophobic pocket, surrounded by residues Phe-414, Pro-291, Pro-212, and Pro-213, forming a stable hydrophobic binding region (Figures 6A, B). Detailed analysis indicates that the B ring of API forms a CH–π interaction with the side chain of residue Phe-414. Furthermore, anion–π interactions were observed between the A ring of API and residues Asp-298 and Glu-214 (Figure 6C). Notably, the carbonyl oxygen of the hydroxyl group at C-7 of API forms hydrogen bonding interactions with residue Glu-214 (bond length: 2.6 Å). These interactions helped API to anchor in the binding site of SIRT1. In addition, the estimated binding energy of API is -7.4 kcal/mol, suggesting that API is an agonist of SIRT1. In summary, the above molecular simulations elucidated the interactions between API and SIRT1, providing valuable information for the further development of SIRT1 agonists.

**API Prevents APAP-Induced Liver Injury by Up-Regulating SIRT1 In Vivo**

To check if the results for EX-527 could be recapitulated in mice, H&E staining, ALT/AST activities, and liver MPO, ROS, MDA,
FIGURE 5 | SIRT1 inhibitor EX-527 reverses the anti-inflammation and antioxidant effects of apigenin (API) in L-02 cells. (A) Nuclear localisation of p65 and NRF2 determined by western blot with acetaminophen (APAP) (10 mM) for 48 h in L-02 cells and quantified. (B) Protein levels and phosphorylation of NRF2 and p65 determined by western blot with APAP (10 mM) for 48 h in L-02 cells and quantified. (C) mRNA levels of IL-6, TNF-α, and MCP-1 assessed by real-time PCR (RT-PCR) with APAP (10 mM) for 48 h in L-02 cells. (D) Reactive oxygen species (ROS) levels in L-02 cells. (E) mRNA levels of GCLC, GCLM, and HO-1 determined by RT-PCR with APAP (10 mM) for 48 h in L-02 cells. The experiments were performed three times. Data are expressed as mean ± SEM [*p < 0.05, **p < 0.01, ***p < 0.001 compared to APAP; *p < 0.05, **p < 0.01, ***p < 0.001 compared to dimethyl sulfoxide (DMSO)].

FIGURE 6 | Theoretical binding mode of apigenin (API) in the binding site of SIRT1. (A) Front view of the docking mode of API (white) in the binding site of SIRT1 (shown in ribbon representation and coloured by structural elements). (B) Top view of the docking mode of API (white) in the binding site of SIRT1 (presented in ribbon representation and colored by structural elements). (C) Representative amino acid residues surrounding API (white) in the binding pocket of SIRT1.
and GSH levels were examined. All results were consistent with the above in vitro data; API protected against APAP-induced liver damage by promoting SIRT1 (Figures 7A–F). Western blot results indicated that EX-527 (10 mg/kg) inhibited levels of SIRT1 and significantly promoted p53 acetylation in mouse liver compared with DMSO (Figure 7G). We also analyzed protein levels of LC3-II/I by western blot, and found that EX-527 down-regulated LC3-II/I, which indicated that EX-527 inhibited autophagy in mouse liver (Figure 7H). Additionally, analysis of phosphorylation and nuclear localisation of NRF2 showed that EX-527 suppressed transcriptional activation of NRF2 induced by API (Figures 7I, J). Furthermore, RT-PCR indicated that EX-527 repressed mRNA levels of GCLM, GCLC, and HO-1 significantly (Figure 7M). Next, we assessed levels of p65 in mouse liver, and western blot results revealed that EX-527 promoted the phosphorylation of p65 and nuclear translocation of p65 in mouse liver (Figures 7I, J). Meanwhile, EX-527 increased mRNA levels and concentrations of IL-6, TNF-α, and MCP-1 in mouse liver, and concentrations of IL-6, TNF-α, and MCP-1 in mouse serum (Figures 7K, L). These results showed that API prevented APAP-induced liver damage by regulating the SIRT1/p53 axis and promoting autophagy, thereby inhibiting inflammatory responses and oxidative stress in vivo.

**DISCUSSION**

Apigenin (API), widely found in plants and vegetables, is believed to exert anti-tumor, anti-oxidation, anti-inflammatory, and other pharmacological effects (Arango et al., 2015; Venigalla et al., 2015; Feng et al., 2016; Sung et al., 2016). Yang et al. showed the protective effect of API against APAP by enhancing hepatic GSH in mice model (Yang et al., 2013). However, it is well known that within the hepatocyte, APAP is metabolized to NAPQI by CYP450 enzymes. NAPQI (a metabolite of APAP) can deplete cellular GSH in the liver, and lead to oxidative stress-induced liver injury (Jaeschke et al., 2003; Jaeschke et al., 2012). It was unclear whether API alleviated the cytotoxicity of NAPQI or only inhibited APAP metabolism in Yang's article. Hence, the effect of API on APAP drug metabolism should be excluded. In our study, we used the metabolism product of APAP, NAPQI to validate the protective effect of API. The results showed NAPQI suppressed the cell viability of L-20 cells, while with the treatment of API, this inhibition was reversed (Figure 2B). This indicated the API alleviated the cytotoxicity of NAPQI directly.

In our current research, we revealed that SIRT1 is the target of API which could directly bind to. The accumulated evidence indicated that the SIRT1-p53 axis is one of the critical targets in liver failure (Wang et al., 2015; Kulkarni et al., 2016; Nakamura et al., 2017), but its role in liver development is not yet known. The current research suggested that SIRT1 directly interacts with API, and stimulation by API may represent an innovative therapeutic strategy by which SIRT1 may deacetylate p53, promote autophagy, inhibit oxidative stress, and reduce inflammatory responses induced by acetaminophen in a mouse model and in L-02 cells. Importantly, treatment with SIRT1 inhibitor EX-527 aggravated liver injury and reversed the therapeutic action of API both in vivo and in vitro. Consistent with previous studies, we found that direct treatment of hepatocytes, such as L-02 or primary mouse hepatocytes with acetaminophen did not alter the level of SIRT1 (Mobasher et al., 2013). Hepatotoxicity induced by APAP was accompanied by an inflammatory response containing stimulation of resident macrophages like Kupffer cells (Liu and Kaplowitz, 2006; Laskin, 2009; Williams et al., 2011). Patricia et al. (Rada et al., 2018) found that conditioned media from RAW 264.7 macrophages co-cultured with APAP reduced protein levels of SIRT1 in hepatocytes. Thus, in future studies, we will focus on the correlation between Kupffer cells, APAP and API.

Previous studies demonstrated that NRF2 and the NFκB pathway are related to APAP-induced liver injury, and flavonoids can target these pathways to ameliorate hepatotoxicity (Zheng et al., 2015; Pang et al., 2016; Shi et al., 2018). The SIRT1-p53 axis can modulate oxidative stress and inflammatory responses via NRF2 and the NFκB pathway (Yang et al., 2015; Yoon et al., 2016; Khan et al., 2018). Though the antioxidant capacity of API was discovered to contribute to its inhibition on APAP-induced hepatotoxicity (Yang et al., 2013), whether the anti-inflammatory activity of API would similarly contribute to its defense against APAP-induced liver injury is still unknown. In our research, we found that API induced NRF2 and suppressed NFκB activation. In addition, the oxidative stress parameters like MDA amount and ROS formation and inflammatory indices like IL-6, TNF-α, and MCP-1 proved that the alleviation of API against APAP-induced liver oxidative stress and inflammation response injury occurred both in vitro and in vivo.

Previous studies reported that SIRT1 could deacetylated p53 (Luo et al., 2001; Vaziri et al., 2001). SIRT1 specially deacetylated p53 at the K382 acetylation site and negatively regulated the capacity of p53 to promote the level of target genes (Luo et al., 2001; Cheng et al., 2003). The suppression of SIRT1 by a specific inhibitor like EX-527 could induce p53 hyperacetylation and enhance p53-dependent transcriptional activity (Lain et al., 2008). It is found in our study that API promoted SIRT1 activity and deacetylated p53, which up-regulated both the NRF2 pathway and glutathione levels, accompanied by inhibition of ROS production, and this simultaneously down-regulated the NFκB pathway and the secretion of pro-inflammatory cytokines. After using EX-527, an inhibitor of SIRT1, the acetylation of p53 was increased which caused the effect of API reversed both in vitro and in vivo.

Autophagy preforms a vital role in survival mechanisms in response to adverse intracellular events. The autophagy mechanism selectively removes damaged organelles, especially mitochondria. Hence, autophagy defends against cell injury induced by mitochondria (Lum et al., 2005; Tan et al., 2018). Excessive acetaminophen can lead to hepatotoxicity by inducing mitochondrial injury and autophagy. Interestingly, promoting autophagy attenuated APAP-induced liver cell death by removing damaged mitochondria (Ni et al., 2012; Lin et al., 2014;
Apigenin (API) prevents acetaminophen (APAP)-induced liver injury by promoting SIRT1 in vivo. (A) Serum alanine/aspartate aminotransferase (ALT/AST) activities was detected. (B) Representative images of H&E staining of mouse liver sections (×200 and ×400 magnification). (C) Myeloperoxidase (MPO) activity in mice liver tissue was detected. (D) Malondialdehyde (MDA) activity in mice liver tissue was detected. (E) Glutathione (GSH) levels in mice liver tissue was detected. (F) Reactive oxygen species (ROS) levels in mice liver tissue was detected. (G) Liver protein levels of SIRT1 and acetyl-p53 determined by western blot and quantified. (H) Liver protein levels of LC3-II/I determined by western blot and quantified. (I) Nuclear localization of p65 and NRF2 by western blot and quantified. (J) Liver protein levels and phosphorylation of NRF2 and p53 determined by western blot and quantified. (K) Serum protein concentrations of IL-6, TNF-α, and MCP-1 determined by enzyme-linked immunosorbent assay (ELISA) in mice. (L) Liver mRNA levels of GCLC, GCLM, and HO-1 determined by qRT-PCR. Data are expressed as mean ± SEM (n = 8; *p < 0.05, **p < 0.01, ***p < 0.001 compared to vehicle; †p < 0.05, ††p < 0.01, †††p < 0.001 compared to APAP, $p < 0.05, $$$p < 0.001 compared to dimethyl sulfoxide (DMSO)).
Yan et al., 2018). After inhibiting autophagy, APAP-mediated hepatotoxicity is aggravated. However, rapamycin, an autophagy promoter, could alleviate APAP-induced liver injury (Ni et al., 2012). Earlier research reported the effect of API on autophagy. Fang et al. found that API promoted autophagy and alleviated myocardial oxidative and inflammatory injury, and endotoxin-induced myocardial toxicity (Li et al., 2017). Additionally, API plays an anti-tumor role by promoting autophagy in various tumors such as skin cancer (Bridgeman et al., 2016), colon cancer (Lee et al., 2014; Chen et al., 2019), thyroid carcinoma (Zhang et al., 2015), and hepatocellular carcinoma (Gao et al., 2018; Yang et al., 2018). Moreover, SIRT1 can directly deacetylate major proteins of autophagy, like Atg5 and Atg8, remove them from the inhibitory state, and thus stimulating autophagy (Ma et al., 2016). At the same time, SIRT1 could also promote autophagy by deacetylating p53 (De et al., 2018). In the present study, we showed that API could interact with SIRT1 and thereby activate autophagy, which reversed damage caused by APAP in hepatocytes.

CONCLUSIONS

In conclusion, we revealed that API promotes autophagy through the SIRT1-p53 axis, and ameliorates oxidative stress and inflammation responses, potentially reversing liver-mediated APAP injury (Figure 8).

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding authors.

ACKNOWLEDGMENTS

We thank International Science Editing (http://www.internationalscienceediting.com) for editing this manuscript.

FIGURE 8 | Schematic representation of proposed mechanism of API on the prevention of APAP-induced liver injury.

ETHICS STATEMENT

The animal study was reviewed and approved by Experimental Animal Ethical Committee of Shanghai University of Traditional Chinese Medicine.

AUTHOR CONTRIBUTIONS

LZ, JZ, and CH: performed the research. GJ, QC, YJ: designed the research study. TW, JL, and CW: contributed essential reagents or tools. LC and MJ: collected the data. JZ and CH: analyzed the data. LZ and JZ: wrote the paper.

FUNDING

This work was financially supported by National Natural Science Foundation of China (81703879); Clinical research project of Shanghai Municipal Commission of health (201840377, 201940449); Putuo District of Shanghai Science And Technology Commission Research Project(ptkwsw201813, ptkwsw201806); Key specialties of Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (2016103A); the Budget Project of Shanghai University of Traditional Chinese Medicine (2016YSN60); and the Budget of Experiment Center for Science and Technology (18LK022)
REFERENCES

Arango, D., Diosa-Toro, M., Rojas-Hernandez, L. S., Cooperstone, J. L., Schwartz, S. I., Mo, X., et al. (2015). Dietary apigenin reduces LPS-induced expression of miR-155 restoring immune balance during inflammation. *Mol. Nutr. Food Res.* 59 (4), 763–772. doi: 10.1002/mnfr.201400705

Bridgeman, B. B., Wang, P., Ye, B., Pelling, J. C., Volpert, O. V., and Tong, X. (2016). Inhibition of mTOR by apigenin in UVB-irradiated keratinocytes: A new implication of skin cancer prevention. *Cell Signal* 28 (5), 460–469. doi: 10.1016/j.cellsig.2016.02.008

Cao, D., Wang, M., Qiu, X., Liu, D., Jiang, H., Yang, N., et al. (2019). Apigenin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant colon cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway. *J. BUON* 24 (2), 488–493.

Cheng, H. L., Mostoslavsky, R., Saito, S., Manis, J. P., Gu, Y., Patel, P., et al. (2003). Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. *Proc. Natl. Acad. Sci. U. S. A.* 100 (19), 10794–10799. doi: 10.1073/pnas.1731310100

Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Cao, D., Wang, M., Qiu, X., Liu, D., Jiang, H., Yang, N., et al. (2019). Apigenin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant colon cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway. *J. BUON* 24 (2), 488–493.

Zhao et al. API Prevents APAP-Induced Liver Injury

Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Cao, D., Wang, M., Qiu, X., Liu, D., Jiang, H., Yang, N., et al. (2019). Apigenin inhibits in vitro and in vivo tumorigenesis in cisplatin-resistant colon cancer cells by inducing autophagy, programmed cell death and targeting m-TOR/PI3K/Akt signalling pathway. *J. BUON* 24 (2), 488–493.

Zhao et al. API Prevents APAP-Induced Liver Injury

Kulkarni, S. R., Soroka, C. J., Hagey, L. R., and Boyer, J. L. (2016). Sir2uin 1 activation alleviates cholestatic liver injury in a cholic acid-fed mouse model of cholestasis. *Hepatology* 64 (6), 2151–2164. doi: 10.1002/hep.28826

Lain, S., Hollick, J. J., Campbell, J., Staples, O. D., Higgins, M., Aoubala, M., et al. (2008). Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. *Cancer Cell* 13 (5), 454–463. doi: 10.1016/j.ccr.2008.03.004

Laskin, D. L. (2009). Macrophages and inflammatory mediators in chemical toxicity: a battle of forces. *Chem. Res. Toxicol.* 22 (8), 1376–1385. doi: 10.1021/tr900086v

Lee, Y., Sung, B., Kang, Y. J., Kim, D. H., Jang, J. Y., Hwang, S. Y., et al. (2014). Apigenin-induced apoptosis is enhanced by inhibition of autophagy formation in HCT116 human colon cancer cells. *Int. J. Oncol.* 44 (5), 15099–11606. doi: 10.3892/ijo.2014.2339

Lee, W. M. (2008). Acetaminophen-related acute liver failure in the United States. *Hepatol. Res.* 38 Suppl 1, S3–S8. doi: 10.1111/j.1872-034X.2008.00419.x

Li, F., Fang, L., Zhang, H., Xu, L., Wang, Y., Zhai, C., et al. (2017). Apigenin Alleviates Endotoxin-Induced Myocardial Toxicity by Modulating Inflammation, Oxidative Stress, and Autophagy. *Oxid. Med. Cell Longev.* 2017, 2302896. doi: 10.1155/2017/2302896

Lin, Z., Wu, F., Liu, S., Pan, S., Lin, L., Lu, T., et al. (2014). Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute kidney injury by promoting autophagy in mice. *J. Hepatol.* 61 (4), 825–831. doi: 10.1016/j.jhep.2014.05.033

Liu, Z. X., and Kaplowitz, N. (2006). Role of innate immunity in acetaminophen-induced hepatotoxicity. *Expert Opin. Drug Metab. Toxicol.* 2 (4), 493–503. doi: 10.1517/17425255.2.4.493

Lum, J. J., Bauer, D. E., Kong, M., Harris, M. H., Li, C., Lindsten, T., et al. (2005). Growth factor regulation of autophagy and cell survival in the absence of apoptosis. *Cell* 120 (2), 237–248. doi: 10.1016/j.cell.2004.11.046

Luo, J., Nikolaev, A. Y., Imai, S., Chen, D., Su, F., Shihol, A., et al. (2001). Negative control of p53 by Sir2alpha promotes cell survival under stress. *Cell* 107 (2), 137–148. doi: 10.1016/S0092-8674(00)00524-4

Ma, L., Fu, R., Duan, Z., Lu, J., Gao, J., Tian, L., et al. (2016). Sirt1 is essential for resveratrol enhancement of hypoxia-induced autophagy in the type 2 diabetic nephropathy rat. *Pathol. Res. Pract.* 212 (4), 310–318. doi: 10.1016/j.prp.2016.02.001

Mobasher, M. A., Gonzalez-Rodriguez, A., Santamaria, B., Ramos, S., Martin, M. A., Goya, L., et al. (2013). Protein tyrosine phosphatase 1B modulates the SIRT1/P53/BAX Pathway. *J. BUON* 18 (9), 2743. doi: 10.3390/ijms19092743

Naini, R., Chikati, R., Vudum, D. R., and Kancha, R. K. (2019). Molecular docking analysis of imine stilbene analogs and evaluation of their anti-aging activity using yeast and mammalian cell models. *J. Recept Signal Transduct Res.* 39 (1), 55–59. doi: 10.1080/17425255.2019.1605529

Nakamura, K., Zhang, M., Kageyama, S., Ley, F., Fujii, T., Sosa, R. A., et al. (2017). Macrophage heme oxygenase-1-SIRT1-p53 axis regulates sterile inflammation in liver ischemia-reperfusion injury. *J. Hepatol.* 67 (6), 1232–1242. doi: 10.1016/j.jhep.2017.08.010

Ni, H. M., Bockus, A., Boggess, N., Jaeschke, H., and Ding, W. X. (2012). Lessons learned from acetaminophen hepatotoxicity. *Drug Metab. Rev.* 55 (4), 823. doi: 10.1080/10799893.2012.6666288

Nourjah, P., Ahmad, S. R., Karwoski, C., and Willy, M. (2006). Estimates of acetaminophen (Paracetamol)-associated overdoses in the United States. *Pharmacoepidemiol. Drug Saf.* 15 (6), 398–405. doi: 10.1002/ps.1191

Pang, C., Zhang, Z., Shi, L., Sheng, Y., Wei, H., Wang, Z., et al. (2016). Caffeic acid prevents acetaminophen-induced liver injury by activating the Keap1-Nrf2 antioxidative defense system. *Free Radic. Biol. Med.* 91, 236–246. doi: 10.1016/j.freeradicbiomed.2015.12.024

Qin, W., Xie, W., Yang, X., Xia, N., and Yang, K. (2016). Inhibiting microRNA-449 Attenuates Csiplatin-Induced Injury in NRK-52E Cells Possibly via Regulating the SIRT1/P53/BAX Pathway. *Med. Sci. Monit.* 22, 818–823. doi: 10.12659/msm.897187
Rada, P., Pardo, V., Mobasher, M. A., Garcia-Martinez, I., Ruiz, L., Gonzalez-Rodriguez, A., et al. (2018). SIRT1 Controls Acetaminophen Hepatotoxicity by Modulating Inflammation and Oxidative Stress. *Antioxid. Redox Signal* 28 (13), 1187–1208. doi: 10.1089/ars.2017.7373

Sanner, M. F. (1999). Python: a programming language for software integration and development. *J. Mol. Graph Model* 17 (1), 57–61. doi: 10.1016/S1093-3263(99)99999-0

Shah, S. A., Yoon, G. H., Kim, H. O., and Kim, M. O. (2015). Vitamin C neuroprotection against dose-dependent glutamate-induced neurodegeneration in the postnatal brain. *Neurochem. Res.* 40 (5), 875–884. doi: 10.1007/s11064-015-1540-2

Shen, T., Liu, Y., Shang, J., Xie, Q., Li, J., Yan, M., et al. (2019). Incidence and Etiology of Drug-Induced Liver Injury in Mainland China. *Gastroenterology* 156(2230–2241 (8), e2211. doi: 10.1053/j.gastro.2019.02.002

Shi, L., Hao, Z., Zhang, S., Wei, M., Lu, B., Wang, Z., et al. (2018). Baicalin and baicainl alleviate acetaminophen-induced liver injury by activating Nrf2 antioxidative pathway: The involvement of ERK1/2 and PKC. *Biochem. Pharmacol.* 150, 9–23. doi: 10.1016/j.bcp.2018.01.026

Simeonova, R., Kondeva-Burdina, M., Vitcheva, V., Krasteva, I., Manov, V., and Mitcheva, M. (2014). Protective effects of the apigenin-O/C-diglucoside saponarin from Gypsophila trichotoma on carbene tetrachloride-induced hepatotoxicity in vitro/in vivo in rats. *Phytochemistry* 21 (2), 148–154. doi: 10.1016/j.phymed.2013.07.014

Sung, B., Chung, H. Y., and Kim, N. D. (2016). Role of Apigenin in Cancer Prevention via the Induction of Apoptosis and Autophagy. *J. Cancer Prev.* 21 (4), 216–226. doi: 10.15430/JCP.2016.21.4.216

Tan, J., Wang, M., Song, S., Miao, Y., and Zhang, Q. (2018). Autophagy activation promotes removal of damaged mitochondria and protects against renal tubular injury induced by albumin overload. *Histol. Histopathol.* 33 (7), 681–690. doi: 10.14670/HHH-11-962

Trott, O., and Olson, A. J. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* 31 (2), 455–461. doi: 10.1002/jcc.21334

Tsaroucha, A. K., Tsaoiosidou, A., Ouzounidis, N., Tsaldidou, E., Lambropoulou, M., Giakoustitis, D., et al. (2016). Intraperitoneal administration of apigenin in liver ischaemia/reperfusion injury protective effects. *Saudi J. Gastroenterol.* 22 (6), 415–422. doi: 10.4103/1319-3767.195556

Vaziri, H., Dessain, S. K., Ng Eaton, E., Imai, S. I., Choi, Y., and Lee, J. W. (2016). Cellular localization of Nrf2 determines the self-renewal and osteogenic differentiation potential of human MSCs via the P53–SIRT1 axis. *Cell Death Dis.* 7, e2093. doi: 10.1038/cddis.2016.3

Zhao, J., Pi, C., and Wang, G. (2018). Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. *BioMed. Pharmacother.* 103, 699–707. doi: 10.1016/j.biopha.2018.04.072

Yoon, D. S., Choi, Y., and Lee, J. W. (2016). Cellular localization of Nrf2 and degradation of SIRT1 form a positive feedback loop to regulate p53 acetylation during heat-shock stress. *Cell Death Dis.* 6, e1747. doi: 10.1038/cddis.2015.106

Yang, J., Pi, C., and Wang, G. (2018). Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. *BioMed. Pharmacother.* 103, 699–707. doi: 10.1016/j.biopha.2018.04.072

Zhao, L., Cheng, X., Gao, Y., Zheng, J., Xu, Q., Sun, Y., et al. (2015). Apigenin induces autophagic cell death in human papillary thyroid carcinoma BCPAP cells. *Food Funct.* 6 (11), 3464–3472. doi: 10.1039/c5fo00671f

Zhao, J., Zhang, J., Pan, L., Chen, L., Wang, Y., Liu, X., et al. (2019). Protective effect of 7,3′,4′-flavan-3-ol (flavetin) on acetaminophen-induced hepatotoxicity in vitro and in vivo. *Phytochemistry* 58, 152865. doi: 10.1016/j.phytochemistry.2019.152865

Zheng, Z., Sheng, Y., Lu, B., and Ji, L. (2015). The therapeutic detoxification of chlorogenic acid against acetaminophen-induced liver injury by ameliorating hepatic inflammation. *Chem. Biol. Interact.* 238, 93–101. doi: 10.1016/j.cbi.2015.05.023

Zhou, R. J., Ye, H., Wang, F., Wang, J. L., and Xie, M. L. (2017). Apigenin inhibits d-galactosamine/LPS-induced liver injury through upregulation of hepatic Nrf-2 and PPARgamma expressions in mice. *Biochem. Biophys. Res. Commun.* 493 (1), 625–630. doi: 10.1016/j.bbrc.2017.08.141

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.